INTRODUCTION: Hepatic magnetic resonance elastography (MRE) allows for noninvasive assessment of liver @entity82 . The purpose of this study was to evaluate the usefulness of MRE in detecting and quantifying liver @entity82 in @entity1 with @entity309 ( @entity309 ) who have received @entity1499 ( @entity6822 ). METHODS: The association between mean liver stiffness value as determined by MRE and variables of interest was determined. The decision for a liver biopsy in @entity1 with an abnormal liver stiffness was made based on clinical judgment. RESULTS: Sixty-five @entity309 @entity1 were enrolled. Mean liver stiffness value by MRE was abnormal in 7 @entity1 , suggestive of @entity99 . As a result of findings from the MRE, biopsies were performed in 5 @entity1 and all correlated with elevated liver stiffness values. Elevated mean liver stiffness values were associated with body mass index (BMI) (OR= 1.18 per 1 kg/m(2); 95% CI: 1.03, 1.36; p=0.017). Neither the total @entity6822 dose nor the duration of @entity6822 treatment was associated with mean liver stiffness value (p=0.51 and P=0.20, respectively). CONCLUSIONS: MRE provides a reliable, non-invasive assessment of liver @entity82 in @entity1 with @entity309 receiving @entity6822 . @entity1 with @entity309 receiving @entity6822 who have an elevated BMI may be at increased risk for @entity99 , regardless of @entity6822 cumulative dose or duration of treatment.

Magnetic Resonance Elastography for Liver Fibrosis in XXXX Treatment.

@entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic injury', 'chronic hepatic injury'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity1499 :: (MESH:D008727,Chemical) :: ['Methotrexate']
